Skip to main content
300 Collins St Melbourne hello@pivot.net
Login Signup
Home Home

Main navigation

  • About
    • Senior Management
    • Leadership
    • Board of Directors
    • Advisors
    • Contact
  • Research & Development
    • Innovation Engine
    • Therapeutic Focus
    • Development Strategy
    • Scientific Presentations
  • Pipeline
    • RMC-4630 (SHP2)
    • RMC-5552 (mTORC1/4EBP1)
    • SOS1
    • RAS(ON) Inhibitors
    • EXPANDED ACCESS POLICY
  • Investors
  • Careers
background

Scientific Presentations

The information included below was provided in connection with a presentation or publication on the date indicated and is qualified as such. Revolution Medicines disclaims any duty to update these materials.

 

 

Publication / Presentation

December 19, 2022

Discovery of RMC-5552, a Selective Bi-Steric Inhibitor of mTORC1, for the Treatment of mTORC1-Activated Tumors

Read more

Publication / Presentation

October 27, 2022

Enhancement of anti-tumor immunity in immunogenic and immune-refractory RAS mutant tumors with tri-complex RAS(ON) inhibitors

Read more

Publication / Presentation

June 7, 2022

The Bi-steric mTORC1-Selective Inhibitor RMC-5552 in Tumors with Activation of mTOR Signaling: Preclinical Activity in Combination with RAS(ON) Inhibitors in RAS-Addicted Tumors, and Initial Clinical Findings from A Single Agent Phase 1/1b Study

Read more

Publication / Presentation

April 12, 2022

RMC-9805 (RM-036), a First-in-Class, Orally-Bioavailable, Tri-Complex Covalent KRAS-G12D(ON) Inhibitor, Drives Profound Anti-Tumor Activity in KRAS-G12D Mutant Tumor Models

Read more

Publication / Presentation

April 12, 2022

A First-In-Class Tri-complex KRAS-G13C(ON) Inhibitor Validates Therapeutic Targeting of KRAS-G13C and Drives Tumor Regressions in Preclinical Models

Read more
VIEW ALL
© Revolution Medicines, Inc.  |  700 Saginaw Drive, Redwood City, CA 94063
CCPA Notice | Privacy Policy
Get in touch with us